A Natural Choice

NUWIQ^® is expressed in a human cell line.
B-domain deleted.
No chemical modifications.

Learn More

Proven Efficacy

Prophylaxis with NUWIQ reduced the frequency of bleeding in adults and children with severe Hemophilia A.

Learn More

Safe for PUPs

The NuProtect study results confirm a low rate of inhibitors with NUWIQ in PUPs.¹

Learn More

Free Trial

A great opportunity for Hemophilia A patients and their providers to experience the safety, effectiveness, and convenience of NUWIQ at no cost.

Learn More

Co-Pay Assistance

The Octapharma Co-Pay Assistance Program available through Factor My Way can provide savings on some of the costs associated with your patients’ treatment.

Learn More

References

Liesner, R. J., et al. Thromb Haemost. 2021;121(11): 1400-1408.

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Usage

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please see NUWIQ full Prescribing Information. Instructions For Use

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)

A Natural Choice NUWIQ® is expressed in a human cell line. B-domain deleted. No chemical modifications.

Proven Efficacy

Safe for PUPs

Free Trial

Co-Pay Assistance

References

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

PUP Inhibitor Study Final Results

A Natural Choice

NUWIQ^® is expressed in a human cell line.
B-domain deleted.
No chemical modifications.